Internal Medicine, Gastroenterology · Santa Ana, CA
NPI
1811061468
Since 2006
Specialty
Internal Medicine, Gastroenterology
Code 207RG0100X
Group practices
1
Medicare group memberships
Hospitals
2
Hospital affiliations
202 N. Euclid, 201
Santa Ana, CA, 92703
Phone (714) 531-3535
Groups this clinician bills Medicare through
Medicare paid, 2024
$216K
1,996 services
Medicare patients, 2024
973
Average age 77
Drug cost, 2024
$6.2M
12,234 prescriptions
Company payments, 2025
$14K
From 20 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Christopher D Bui was code 99214 (office e&m - established), 1,510 times for 862 patients. In total Christopher D Bui billed 1,996 services in 16 codes, and Medicare paid $216K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2014-04-03.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 1,510 | 862 | $99.93 | $151K |
| 99204 Office E&M - New | Office | 183 | 183 | $131.68 | $24K |
| 43239 Upper GI Endoscopy | Facility | 102 | 102 | $105.79 | $11K |
| 45380 Lower GI Endoscopy - Other | Facility | 49 | 49 | $154.43 | $7,567 |
| 76981 Ultrasound - Nonspecific | Office | 43 | 43 | $86.57 | $3,722 |
| 45378 Lower GI Endoscopy - Other | Facility | 39 | 39 | $139.41 | $5,437 |
| 45385 Colonoscopy - Lesion Removal | Facility | 36 | 35 | $193.19 | $6,955 |
| 43251 Upper GI Endoscopy | Office | 11 | 11 | $415.24 | $4,568 |
By year: 2022 $349K for 3,101 services; 2023 $300K for 2,620 services; 2024 $216K for 1,996 services.
Medicare prescription drug claims, 2024
In 2024, the drug Christopher D Bui prescribed most often to Medicare patients was Famotidine, with 2,371 prescriptions and refills. In total Christopher D Bui wrote 12,234 Medicare prescriptions that cost $6.2M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Famotidine Generic | 2,371 | 3,813 | 621 | $12K |
| Creon Lipase/Protease/Amylase | 1,112 | 1,174 | 221 | $1.5M |
| Dexlansoprazole Dr Dexlansoprazole | 1,096 | 1,352 | 200 | $217K |
| Pantoprazole Sodium Generic | 885 | 1,508 | 269 | $5,327 |
| Linzess Linaclotide | 873 | 989 | 176 | $524K |
| Vemlidy Tenofovir Alafenamide | 841 | 869 | 98 | $1.2M |
| Zenpep Lipase/Protease/Amylase | 820 | 893 | 160 | $1.4M |
| Entecavir Generic | 584 | 890 | 96 | $118K |
| Baclofen Generic | 412 | 510 | 147 | $2,749 |
| Omeprazole Generic | 403 | 618 | 113 | $1,905 |
| Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates | 273 | 273 | 268 | $17K |
| Sucralfate Generic | 235 | 275 | 75 | $3,609 |
| Voquezna Vonoprazan Fumarate | 212 | 218 | 67 | $137K |
| Trulance Plecanatide | 162 | 184 | 47 | $100K |
| Xifaxan Rifaximin | 137 | 137 | 27 | $429K |
Brand drugs: - claims; generic drugs: 7,589 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Christopher D Bui $14K ($14K in general payments such as food, travel and fees) from 20 companies. The largest payer was Gilead Sciences, Inc. with $6,241.
| Company | Payments | Amount |
|---|---|---|
| Gilead Sciences, Inc. GILD | 17 | $6,241 |
| Abbvie Inc. ABBV | 20 | $4,383 |
| Aimmune Therapeutics, Inc. | 39 | $909 |
| Ardelyx, Inc. ARDX | 20 | $403 |
| Stryker Corporation SYK | 1 | $362 |
| Lilly USA, LLC LLY | 5 | $312 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC BHC | 14 | $258 |
| Madrigal Pharmaceuticals MDGL | 10 | $255 |
| Phathom Pharmaceuticals, Inc. PHAT | 8 | $164 |
| Medtronic, Inc. MDT | 1 | $143 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.